USFDA4 Dec 2025, 12:48 pm
Zydus Lifesciences Receives EIR for Injectable Facility at Jarod from USFDA
AI Summary
Zydus Lifesciences Ltd. has announced that it has received the Establishment Inspection Report (EIR) from the USFDA for a GMP follow-up inspection conducted at its injectable facility located at Jarod, Vadodara from August 25 to September 5, 2025. The facility has been classified as Voluntary Action Indicated (VAI) following the Warning Letter issued on August 29, 2024. This disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Highlights
- Zydus Lifesciences Ltd. receives EIR from USFDA for its injectable facility at Jarod.
- The facility was inspected by the USFDA from August 25 to September 5, 2025.
- The facility has been classified as Voluntary Action Indicated (VAI) by the USFDA.
- The EIR follows a Warning Letter issued by the USFDA on August 29, 2024.
- The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.